BioElectronics ActiPatch Musculoskeletal Therapy Added to Mundipharma Australia’s Pain Portfolio

FREDERICK, MD, July 23, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), is pleased to announce that Mundipharma Pty Limited (Mundipharma), has added ActiPatch® to its pain management portfolio, by acquiring the exclusive Australian and New Zealand distribution rights to the ActiPatch® Musculoskeletal Pain Therapy medical device.

“The addition of ActiPatch® to our existing pain medications confirms our commitment to help clinicians manage pain with a multimodal approach, including non-drug therapies. Our education programs for healthcare professionals emphasize the importance of stepped multimodal pain management, so I’m delighted that we’re now able to offer ActiPatch®,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand.

“We are pleased to have Mundipharma Australia’s professional support, training programs, clinical credentials, and medical and retail representatives educating physicians and pharmacists on the benefits of ActiPatch® Therapy. It is essential for our growing sales and marketing portfolio to be supported and maintained by major healthcare marketers like Mundipharma,” said Keith Nalepka, BioElectronics, VP Sales and Marketing.

About BioElectronics Corporation:

BioElectronics develops, manufactures, and markets unique drug free, noninvasive neuromodulation pain therapy medical devices. The Company’s technology platform is for the treatment of central sensitization, which is now widely accepted as the physiological explanation for many neurological disorders, and specifically, chronic pain.

The products include ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; and, Allay® Menstrual Pain Therapy. For more information, please visit

About Mundipharma Australia:

Mundipharma Pty Limited is a member of a global network of independent associated companies, which are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include treatments for cancer, glaucoma, asthma, burns, wounds, skin irritations and the common cold.

ACTIPATCH is a registered trademark.

Paul Knopick